Transarterial radioembolization for hepatocellular carcinoma: An update and perspectives [PDF]
World Journal of Gastroenterology, 2015 In the last decade trans-arterial radioembolization has given promising results in the treatment of patients with intermediate or advanced stage hepatocellular carcinoma (HCC), both in terms of disease control and tolerability profile.
Bargellini, Irene +16 more
core +4 more sources
Transarterial radioembolization: a systematic review on gaining control over the parameters that influence microsphere distribution. [PDF]
Drug Deliv, 2023 [Purpose] Transarterial radioembolization (TARE) is an established treatment modality for patients with unresectable liver cancer. However, a better understanding of treatment parameters that influence microsphere distribution could further improve the therapy.
Snoeijink TJ +5 more
europepmc +7 more sources
Retrospective SPECT/CT dosimetry following transarterial radioembolization [PDF]
Journal of Applied Clinical Medical Physics, 2021 AbstractTransarterial radioembolization (TARE) effectively treats unresectable primary and metastatic liver tumors through intra‐arterial injection of Yttrium‐90 (90Y) beta particle emitting microspheres which implant around the tumor. Current dosimetry models are highly simplistic and there is a large need for an image‐based dosimetry post‐TARE, which
Briana C. Thompson, William A. Dezarn
+7 more sources
Association Between Discharge Medications and Oncologic Post‐Embolization‐Syndrome‐Related Outcomes
Cancer MedicineBackground Post‐embolization syndrome after transarterial chemoembolization (TACE) and Yttrium‐90 radioembolization (TARE) causes significant morbidity.
Hanzhou Li +10 more
doaj +2 more sources
Current status of transarterial radioembolization
World Journal of Radiology, 2016 Unresectable primary and secondary liver malignancies present a major problem in the treatment of solid tumors. Transarterial radioembolization (TARE) is an increasingly used technique for treating various types of malignant liver tumors. This approach is appealing, as the mechanism of action is independent from other loco-regional treatments and ...
Andreas H. Mahnken
openalex +4 more sources
Transarterial Radioembolization: Overview of Radioembolic Devices. [PDF]
Semin Intervent Radiol, 2023 Serhal M +4 more
europepmc +3 more sources
Combining Immunotherapy with Transarterial Radioembolization. [PDF]
Indian J Nucl Med, 2023 Hepatocellular carcinoma (HCC) has a high mortality rate due to the diagnosis of patients at advanced stages and ineffective systemic therapies. Immunotherapy is considered a new treatment option for unresectable HCC alternatives to the limitations of conventional cytotoxic chemotherapy.
Balaban Genc ZC +3 more
europepmc +3 more sources
Radioembolization Followed by Transarterial Chemoembolization in Hepatocellular Carcinoma [PDF]
Cureus, 2022 In recent years, combination therapies for hepatocellular carcinoma (HCC) have been increasingly used with superior treatment responses compared to monotherapies. However, the safety and efficacy of the transarterial chemoembolization (TACE) and transarterial radioembolization (TARE) combinations for HCC patients have not been investigated in the ...
Baran Vardar +6 more
openalex +3 more sources
Radioembolization for hepatocellular carcinoma: what clinicians need to know [PDF]
Journal of Liver Cancer, 2022 Transarterial radioembolization (TARE) with yttrium 90 (90Y) has been used in the management of hepatocellular carcinoma (HCC) for more than 10 years in Korea.
Jin Woo Choi, Hyo-Cheol Kim
doaj +1 more source
Transarterial Radioembolization in Advanced Stage Hepatocellular Carcinoma
Gastroenterology, 2011 Ju Dong Yang +5 more
openalex +2 more sources